Diagnostic accuracy of
            <sup>68</sup>
            Ga‐PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen

Coşar, Uğur; Şen, İ̇lker; Aydos, Uğuray; Koparal, Murat Yavuz; Uçar, Murat; Tokgöz, Nil; Gönül, İpek Işık; Akdemir, Ümit Özgür; Atay, Lütfiye Özlem; Sözen, Tevfik

doi:10.1111/ijcp.14287

Cited by 6 publications

(2 citation statements)

References 21 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, it is noteworthy that the reported pooled sensitivity (60%) and specificity (89%) values of MRI differ from the established referenced values of higher sensitivity (approximating 90%) and lower specificity (ranging from 37% to 74%) for ISUP grade group ≥ 2 csPCa from studies involving MRI-informed biopsy strategies [ 9 , 20 , 23 , 27 ]. We found analogous discrepancies in more recent studies comparing MRI and PET imaging, which reported an MRI with a 56–68% sensitivity and a 91–92% specificity for csPCa [ 88 , 89 ]. The reasons for such discrepancies may be related to the retrospective nature, small study populations, and high frequency of region-based rather than lesion-based estimation methods of the available studies [ 87 ].…”

Section: Pathways Of Interaction Between Mri and Psma-petsupporting

confidence: 86%

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer

Cereser,

Evangelista,

Giannarini

et al. 2023

Diagnostics

View full text Add to dashboard Cite

Over the last years, prostate magnetic resonance imaging (MRI) has gained a key role in the primary diagnosis of clinically significant prostate cancer (csPCa). While a negative MRI can avoid unnecessary prostate biopsies and the overdiagnosis of indolent cancers, a positive examination triggers biopsy samples targeted to suspicious imaging findings, thus increasing the diagnosis of csPCa with a sensitivity and negative predictive value of around 90%. The limitations of MRI, including suboptimal positive predictive values, are fueling debate on how to stratify biopsy decisions and management based on patient risk and how to correctly estimate it with clinical and/or imaging findings. In this setting, “next-generation imaging” imaging based on radiolabeled Prostate-Specific Membrane Antigen (PSMA)-Positron Emission Tomography (PET) is expanding its indications both in the setting of primary staging (intermediate-to-high risk patients) and primary diagnosis (e.g., increasing the sensitivity of MRI or acting as a problem-solving tool for indeterminate MRI cases). This review summarizes the current main evidence on the role of prostate MRI and PSMA-PET as tools for the primary diagnosis of csPCa, and the different possible interaction pathways in this setting.

show abstract

Section: Pathways Of Interaction Between Mri and Psma-petsupporting

confidence: 86%

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer

Cereser,

Evangelista,

Giannarini

et al. 2023

Diagnostics

View full text Add to dashboard Cite

show abstract

“…The use of PSMA PET improves the management of prostate cancer patients as it outperforms mpMRI (21). In addition, PSMA PET/MRI was found to have a higher clinical diagnostic accuracy in prostate cancer than PSMA PET or mpMRI (22)(23)(24).…”

Section: Discussionmentioning

confidence: 98%

Can 18F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?—A single-center retrospective study

Liu¹,

Niu²,

Luan³

et al. 2023

Transl Androl Urol

View full text Add to dashboard Cite

Background: Of the currently available prostate-specific membrane antigen (PSMA) positron emission tomography (PET) tracers, although 68 Ga-PSMA-11 and 18 F-DCFPyL have been approved by the US Food and Drug Administration (FDA), both tracers are excreted rapidly through the urinary tract, resulting in strong accumulation in the bladder and blurring the prostate. 18 F-PSMA-7Q is a novel quinoline-containing PSMA PET tracer developed by our team, which is primarily excreted through the liver. It can reduce the incidence of urine-induced false-positives in the prostate. We aimed to explore the diagnostic efficacy of 18 F-PSMA-7Q PET/computed tomography (CT), and when 18 F-PSMA-7Q PET/CT can be used instead of prostate biopsy to diagnose prostate cancer.Methods: Patients who underwent 18 F-PSMA-7Q PET/CT for prostate cancer staging or prostate biopsy guidance at our institution between July 2020 and December 2021 were retrospectively enrolled. Molecular imaging PSMA (miPSMA) scores were assigned for intra-prostatic lesions according to the Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria, and the diagnostic efficacy of 18 F-PSMA-7Q PET/CT for different miPSMA scores was evaluated using pathological diagnosis as the gold standard.Results: Of the 125 enrolled patients, 101 had prostate cancer, and 24 had prostatic hyperplasia or prostatitis. miPSMA ≥2 was the optimal diagnostic threshold, and area under curve (AUC) was 0.948, the sensitivity and specificity were 91.1% and 83.0%. The prostate cancer detection rates of 18 F-PSMA-7Q PET/CT were 14.3% (3/21), 60.0% (6/10), 96.7% (58/60), and 100% (34/34) for patients with miPSMA scores of 0, 1, 2, and 3, respectively. There was no significant difference in the detection rate of prostate cancer between groups with miPSMA scores of 2 and 3, but there were significant differences between any other 2 groups. Conclusions:The prostate cancer detection rate of 18 F-PSMA-7Q PET/CT was high for lesions with greater miPSMA scores of 2 and 3. For patients with a high miPSMA score, particularly those with a miPSMA score of 3, prostate biopsy can be omitted and prostate cancer-related treatment can be considered.

show abstract

Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis

Ma,

Yang,

et al. 2023

Eur Radiol

View full text Add to dashboard Cite

Diagnostic accuracy of ⁶⁸ Ga‐PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen

Cited by 6 publications

References 21 publications

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer

Can 18F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?—A single-center retrospective study

Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis

Contact Info

Product

Resources

About

Diagnostic accuracy of 68 Ga‐PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen

Cited by 6 publications

References 21 publications

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer

Prostate MRI and PSMA-PET in the Primary Diagnosis of Prostate Cancer

Can 18F-PSMA-7Q PET/CT replace prostate biopsy for the diagnosis of prostate cancer?—A single-center retrospective study

Head-to-head comparison of prostate-specific membrane antigen PET and multiparametric MRI in the diagnosis of pretreatment patients with prostate cancer: a meta-analysis

Contact Info

Product

Resources

About

Diagnostic accuracy of ⁶⁸ Ga‐PSMA PET/MRI and multiparametric MRI in detecting index tumours in radical prostatectomy specimen